139 related articles for article (PubMed ID: 37796634)
21. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.
Castaldo AJ; Jervelund C; Corcoran D; Boysen HB; Christiansen SC; Zuraw BL
Allergy Asthma Proc; 2021 Mar; 42(2):108-117. PubMed ID: 33581742
[No Abstract] [Full Text] [Related]
22. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate.
Tallroth GA
Int Arch Allergy Immunol; 2011; 154(4):356-9. PubMed ID: 20975289
[TBL] [Abstract][Full Text] [Related]
23. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.
Lumry W; Manning ME; Hurewitz DS; Davis-Lorton M; Fitts D; Kalfus IN; Uknis ME
J Pediatr; 2013 May; 162(5):1017-22.e1-2. PubMed ID: 23312695
[TBL] [Abstract][Full Text] [Related]
24. A recombinant C1 esterase inhibitor (Ruconest) for hereditary angioedema.
Med Lett Drugs Ther; 2016 Mar; 58(1491):e44-5. PubMed ID: 27027690
[No Abstract] [Full Text] [Related]
25. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
Martinez-Saguer I; Cicardi M; Suffritti C; Rusicke E; Aygören-Pürsün E; Stoll H; Rossmanith T; Feussner A; Kalina U; Kreuz W
Transfusion; 2014 Jun; 54(6):1552-61. PubMed ID: 24266596
[TBL] [Abstract][Full Text] [Related]
27. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
28. C1 inhibitor therapy and hereditary angioedema.
Kalfus I; Frank M
Am J Med; 2010 Apr; 123(4):e15; author reply e17. PubMed ID: 20362736
[No Abstract] [Full Text] [Related]
29. Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
Reshef A; Levy D; Longhurst H; Cicardi M; Craig T; Keith PK; Feussner A; Feuersenger H; Machnig T; Prusty S; Pragst I
Thromb Haemost; 2021 May; 121(5):690-693. PubMed ID: 33202446
[No Abstract] [Full Text] [Related]
30. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.
Zuraw BL; Busse PJ; White M; Jacobs J; Lumry W; Baker J; Craig T; Grant JA; Hurewitz D; Bielory L; Cartwright WE; Koleilat M; Ryan W; Schaefer O; Manning M; Patel P; Bernstein JA; Friedman RA; Wilkinson R; Tanner D; Kohler G; Gunther G; Levy R; McClellan J; Redhead J; Guss D; Heyman E; Blumenstein BA; Kalfus I; Frank MM
N Engl J Med; 2010 Aug; 363(6):513-22. PubMed ID: 20818886
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Hereditary Angioedema.
Caballero T
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
[TBL] [Abstract][Full Text] [Related]
33. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week.
Bork K; Hardt J
Int Arch Allergy Immunol; 2011; 154(1):81-8. PubMed ID: 20664282
[TBL] [Abstract][Full Text] [Related]
34. Use of Concentrated Plasma-Derived Subcutaneous C1 Inhibitor as Long-Term Prophylaxis in an 8-Year- Old Child With Hereditary Angioedema.
Lasa EM; Herrero L; Martínez S; Arruti N; Oliver P; Joral A
J Investig Allergol Clin Immunol; 2023 Jul; 33(4):302-304. PubMed ID: 36000819
[No Abstract] [Full Text] [Related]
35. Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program.
Gregory C; Landmesser LM; Corrigan L; Mariano D
J Infus Nurs; 2014; 37(1):29-34. PubMed ID: 24384882
[TBL] [Abstract][Full Text] [Related]
36. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost.
Rasmussen ER; Aagaard L; Bygum A
Ann Allergy Asthma Immunol; 2016 May; 116(5):476-7. PubMed ID: 27017563
[No Abstract] [Full Text] [Related]
37. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
[TBL] [Abstract][Full Text] [Related]
38. Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom.
Ahuja M; Dorr A; Bode E; Boulton APR; Buckland M; Chee S; Dalley C; Denman S; Ekbote A; Elkhalifa S; El-Shanawany T; Eren E; Herwadkar A; Garcez T; Ghanta H; Grammatikos A; Grigoriadou S; Jain R; Lorenzo L; Manson A; Moon E; Murng S; Murphy A; Mutlu L; Peters N; Sooriyakumar K; Stroud C; Townsend K; Yellon RL; Yong P; Kiani-Alikhan S
Allergy; 2023 May; 78(5):1380-1383. PubMed ID: 36609839
[No Abstract] [Full Text] [Related]
39. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.
Magerl M; Frank M; Lumry W; Bernstein J; Busse P; Craig T; Martinez-Saguer I; Riedl MA; Shapiro R; Edelman J; Williams-Herman D; Wood DN; Feuersenger H; Rojavin M;
Ann Allergy Asthma Immunol; 2017 Jan; 118(1):110-112. PubMed ID: 27865714
[No Abstract] [Full Text] [Related]
40. Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Zhang Y; Tortorici MA; Pawaskar D; Pragst I; Machnig T; Hutmacher M; Zuraw B; Cicardi M; Craig T; Longhurst H; Sidhu J
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):158-165. PubMed ID: 29316335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
